The study of 139 stage 1 and 2 cancer patients and 184 controls is the first clinical trial of a platform called high-conductivity dielectrophoresis. It detects extracellular vesicles (EVs) containing tumor proteins that are released into the circulation by cancer cells as part of a poorly understood intercellular communication network. Then, the analysis of protein markers using artificial intelligence is used to predict the likelihood of a malignant tumor.
In addition to detecting stage 1 pancreatic cancer with 99.5% accuracy, this approach detected 74.4% of stage 1 ovarian cancer and 73.1% of lethally aggressive stage 1A pathological serous ovarian adenocarcinomas—all with greater than 99 percent accuracy—illustrating the potential the value of this technology for the early detection of cancer. News items cannot be equated with a doctor’s prescription. Before making a decision, consult with a specialist.